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Abstract 
 
Importance: In 2017, 47,600 Americans died of an opioid overdose. Medication assisted 
treatment is effective at treating opioid use disorder, but it is not available at most substance 
abuse treatment centers. Expanding insurance coverage may motivate treatment centers to add 
the capacity to provide MAT.  
 
Objective: To determine whether or not the ACA Medicaid expansion caused more treatment 
centers to add the ability to prescribe drugs for MAT. 
 
Design and Data: This quasi-experimental study uses a difference-in-differences design 
exploiting the variation in the date states expanded their Medicaid programs. The data is 
provided by the 2011-2017 National Survey of Substance Abuse Treatment Services (N-
SSATS), conducted annually by SAMHSA. This survey includes roughly 14,000 treatment 
centers every year. Data were aggregated to the expansion group-year level. A difference-in-
differences regression model was estimated for changed in the percent of centers offering MAT 
in expansion states vs non-expansion states.  
 
Outcome variable: Percent of centers offering MAT 
 
Results: The difference-in-differences analysis estimates a very slight difference in the percent 
of centers offering MAT before and after the expansion of Medicaid in 2014 between expansion 
and non-expansion states, producing a confidence interval of (-4.11%, 4.87%) centered at a 
mean of 0.38%. This estimate is insignificant.  
 
Conclusion and Implications: The Medicaid expansion had no significant effect on the percent 
of centers choosing to offer MAT. In order to increase access to MAT, policy makers will have 
to consider alternate incentives to motive treatment centers to add capacity.  
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Introduction 
In 2017, 47,600 people in the United States died from an overdose of an opioid. 
Prescription opioids caused 40% of these deaths, while heroin, fentanyl, and other non-
prescription opioids caused the other 60% of deaths. An estimated 11.4 million people misused 
prescription opioids in 2017, roughly 4% of the overall population. 2.1 million people had an 
opioid use disorder (OUD) in 2017, defined as a problematic pattern of opioid use leading to 
clinically significant impairment or distress by the CDC. OUD is commonly referred to as opioid 
addiction (U.S. Department of Health and Human Services, What is the U.S. Opioid Epidemic? 
2019). The death rate due to opioid overdose has risen drastically in the last five years of data—
from 7.4 deaths per 100,000 population in 2012 to 14.9 in 2017 (CDC, U.S. Opioid Prescribing 
Rate Maps 2018). The increasing trend shows no sign of relenting, prompting the public and 
lawmakers to ask how the country plunged into such a crisis.  
Historically, the United States has been somewhat afraid of opiates and viewed pain as an 
inevitable symptom. In 1914, the government passed the Harrison Narcotic Control Act in 
response to the marketing of heroin and cocaine for common ailments. This act made it illegal to 
possess morphine and other narcotics without a prescription. Doctors hesitated to prescribe 
opioids throughout the mid-1900s under the belief that they were addictive (Jones et el. 2018). 
This began to change in the 1980s. In 1985, JP. Morgan published an article that stated that 
doctors undertreated severe pain because of an irrational fear that patients would become 
addicts—a concept he called “opiophobia” (Morgan 1985). A 1993 paper stated that opiophobia 
prohibited 50-80% of cancer patients in Europe from receiving adequate pain relief, a situation 
that it argued needed to be rectified immediately. The paper also reaffirmed that loosening 
prescribing laws for opioids would not lead to an increase in deaths, saying, “In France, 
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consumption of morphine for medical use increased by 650% during the years 1986 to 1990 but 
drug deaths rose by only 89%” as proof (Zenz and Willweber-Strumf 1993, 1076).  
 Medical governing bodies quickly began to change their views. In 1986, the World 
Health Organization published a brief blaming “fears concerning ‘addiction’ both in cancer 
patients and in the wider public if strong opioids are more readily available for medicinal 
purposes” as one of the four reasons for unsatisfactory pain treatment in cancer patients (Cancer 
Pain Relief 1986, 13). The American Pain Society launched a campaign naming pain as the fifth 
vital sign in 1995, which the Veteran’s Health Administration adopted in 1999. The DEA and 
Federation of State Medical Boards promised less regulation of opioids, and the Joint 
Commission added standards that required accredited doctors and organizations to make a 
quantitative assessment of patient pain in 2000 (Jones et el. 2018). A 2016 statement issued by 
the Joint Commission characterizes the literature prior to 2000 as a “national outcry about the 
widespread problem of undertreatment of pain” and asserts that the guidelines never advocated 
for pain as a fifth vital sign or for the use of opioids to treat pain (Baker 2016). 
 One of the main factors enabling the sudden acceptance of the use of opioids for acute 
and chronic pain was the newfound belief that opioids did not cause addiction, based on two 
main sources. The first, a single-paragraph letter to the editor published in the New England 
Journal of Medicine in 1980, stated that of 11,882 patients treated with narcotics in a hospital, 
only four (0.03%) showed signs of an addiction afterwards. With over 360 citations, this letter is 
considered so important to the now debunked belief that opioids are not addictive that the journal 
published an accompanying disclaimer “for reasons of public health” in 2017 (Porter and Jick 
1980). The second source, published in 1986, showed that only 2 of 38 patients treated with 
various opioids in a hospital became dependent afterwards, both of whom had a history of drug 
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abuse. It concludes that opioid maintenance therapy can be safe and sustainable (Portenoy and 
Foley 1986).  
 The number of opioid prescriptions written annually increased from 76 million in 1991 to 
255 million in 2012. The prescription rate per 100 people has been falling since that year, fueled 
by doctors’ increased awareness of the dangers of opioids, but deaths due to overdoses of opioids 
continue to rise (see Figure 1). This continued increase may be attributable to the observed 
behavior of some people who lose access to prescription opioids and switch to more potent street 
drugs, like heroin or fentanyl (Alpert, Powell and Pacula 2018). Strategies to curb the crisis need 
to address treatment of OUD as much as they must address supply of opioids.  
Figure 1:  
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Medication Assisted Treatment  
 One way to treat OUD is through medication assisted treatment, or MAT. This form of 
treatment uses a set of pharmacotherapy drugs that limit a person’s craving for opioids. There are 
three main drugs used for MAT. The first drug is methadone, an opioid that blocks receptors in 
the brain that might respond to other opioids. It does not produce a feeling of euphoria but does 
relieve pain associated with withdrawal. Patients undergoing methadone maintenance typically 
receive one dose per day, administered in an addiction treatment facility, for anywhere from six 
months to three years. Only certified Opioid Treatment Programs (OTPs) can dispense 
methadone. By law, OTPs must also provide counseling and other assessment services to 
patients receiving methadone maintenance. To become an OTP, a treatment center must seek 
certification from SAMHSA and accreditation from an independent, SAMHSA-approved 
accreditation body. The center must also be licensed by the state and renew its accreditation 
every year (SAMHSA, Certification of OTPs 2015). 
 The second main MAT drug is buprenorphine, approved in 2002 for clinical use. 
Buprenorphine is an opioid partial agonist, meaning that it produces similar but weaker effects 
than opioids like heroin. Unlike methadone, buprenorphine can be prescribed to a patient for use 
outside of the treatment facility. It is often paired with naloxone, an opioid antagonist, which 
blocks the effect of the buprenorphine if the pill is crushed and injected or otherwise misused. 
Buprenorphine can be prescribed by an OTP or by a doctor who has completed the eight-hour 
SAMHSA training (SAMHSA, Buprenorphine 2019). The final drug is naltrexone, an opioid 
antagonist. Unlike buprenorphine and methadone, which activate opioid receptors in the brain, 
naltrexone binds and blocks receptors. There is very little abuse potential with naltrexone. Any 
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doctor who is certified to prescribe medications can prescribe naltrexone (SAMHSA, Medication 
and Counseling Treatment 2019).  
 In 2017, 40% of substance abuse treatment centers in the nation offered at least one of 
these drugs used for MAT, up from 31.4% in 2011. The mix of MAT drug offerings has changed 
since 2011 as well. The percent of centers offering methadone hovered between 11 and 12% 
from 2011 to 2016 but dropped to 9.4% in 2017. Both oral and injectable (extended release) 
naltrexone, along with buprenorphine with and without naloxone, saw a sharp and steady rise in 
popularity during the period. Figure 2 shows these trends. This can partly be attributed to the 
difficulty of the OTP certification process compared to the certification process to prescribe 
buprenorphine or naltrexone. Patients also do not have to travel to the treatment center every day 
to receive naltrexone or buprenorphine, as they do with methadone.  
Figure 2: 
 
 9 
 
The percent of centers that offer MAT is also not constant across states. In 2017, 15% of 
substance abuse treatment centers in Arkansas offered at least one type of MAT, while 74% of 
centers in New York did. Generally, states in the Northeast and upper Appalachian regions have 
a higher rate of MAT offered. Figure 3 shows this regional variation.  
Figure 3: 
 
 
MAT has been shown to be more effective than other methods of substance abuse 
treatment. According to SAMHSA, MAT significantly reduces the need for inpatient 
detoxification services for those with OUD. It also increases patient survival and patient 
retention in treatment, decreases illicit opioid use and crime among those with MAT, increases 
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patient ability to work, and improves birth outcomes for women with OUD (SAMHSA, 
Medication and Counseling Treatment 2019). However, only 11-26% of patients with OUD 
receive treatment, and of those, only a third receive MAT (Knudsen, Abraham and Roman 
2011). 
 
Medicaid Expansion 
On March 23rd, 2010, the Patient Protection and Affordable Care Act was signed into law 
by President Obama. Among other provisions to increase Americans’ access to health insurance 
and care, the ACA expanded Medicaid to cover all individuals under 138% of the federal poverty 
line, to take effect January 1st, 2014. Prior to 2010, each individual state ran its own Medicaid 
program, deciding whom and what to cover. These programs were supported financially by the 
federal government but administered and organized by the state. To expand Medicaid coverage, 
the ACA stipulated that the states would lose federal financial backing for their existing 
Medicaid programs if they did implement an expanded Medicaid program, though the expansion 
would be paid for almost entirely by the federal government. The Supreme Court ruled on June 
28, 2012 that this maneuver was unconstitutionally coercive in the case Florida v. Dept. of 
Health and Human Services, giving states a reasonable choice whether or not to expand their 
Medicaid program in 2014. Half of the states chose to do so in 2014. As of April 2019, 36 states 
and the District of Columbia have elected to expand their Medicaid programs (KFF, Status of 
State Medicaid Expansion Decisions 2019). By law, expanded Medicaid must cover prescription 
pain medication including opioids, as well as treatment for addiction including MAT.  
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Prior Literature 
Insurance Coverage and Medicaid Expansions 
Research has so far shown that the Medicaid expansion increased insurance coverage in 
expansion states, both among low-income individuals and the population as a whole. The first 
study to use nationally representative data found that the number of people covered by Medicaid 
in expansion states increased 10.5 percentage points compared to non-expansion states. The 
percentage of people reporting no insurance coverage dropped 7.4 percentage points. Visits to a 
general physician and days stayed in hospital increased significantly, along with a small handful 
of diagnostic frequencies (Wherry and Miller 2016). Prior work had shown that by the second 
quarter of 2014, the uninsured rate had dropped 6 percentage points for people with income 
below 138% of the poverty line in states that had expanded Medicaid, but only 3.1 percentage 
points in states that had not expanded Medicaid. Only the result for the expansion states was 
significant. The study used the Gallup-Healthways Well-Being Index, as federal data had not yet 
been released (Sommers et al. 2014). The Urban Institute also showed that the uninsured rate had 
dropped more in Medicaid expansion states than non-expansion states (52.5 percent drop versus 
30.6 percent drop), but the lack of data from the federal government hindered this work too 
(Long et al. 2015). Another early study, using a differences-in-differences design with the 
Gallup-Healthways WBI again, showed that Medicaid expansion was associated with a 5.2 
percentage point decrease in the uninsured rate among low-income adults (Sommers et al. 2015). 
These results correspond to similar studies finding insurance gains following an 
expansion in Medicaid. Using the Medicaid expansions in Maine (expanded 2002), Arizona 
(expanded 2001), and New York (expanded 2001), Sommers, Baicker, and Epstein (2012) found 
that expansions of Medicaid precipitated a significant increase in Medicaid coverage by 2.2 
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percentage points, or a relative increase of 25 percent. The expansions also were associated with 
a 3.2 percentage point decrease in the uninsured rate in these states, also statistically significant 
(Sommers, Baicker and Epstein 2012). 
Later studies on the ACA Medicaid expansion using federal data found similar effects to 
the earlier ones. Three years after the first ACA Medicaid expansions went into effect, 
Courtemanche et al. (2017b) found the expansion increased the insurance rate by 5.9 percentage 
points in expansion states. States that did not expand Medicaid saw only a 2.8 percentage point 
increase in the insurance rate. The study uses data from the Census Bureau American 
Community Survey for 2011 to 2014 and isolated the effect of the Medicaid expansion versus 
the ACA as a whole, finding that the Medicaid expansion in expansion states was responsible for 
3.1 percentage points of the overall increase in insurance rate. Using the ACS and additional data 
from the Current Population Survey, Kaestner et al. (2017) found the Medicaid expansion to be 
associated with a 50 percent increase in insurance rates among childless adults. This study used 
data on the broader population rather than only low-income adults. 
 Some feared the Medicaid expansion, whether by increasing disposable income or 
providing easier access to addictive drugs, may increase risky health behaviors or use of opioids. 
Research has generally not found this to be the case. A recent study found no significant impacts 
of the Medicaid expansion on a variety of risky behaviors after two years. The study used 
smoking, drinking, and BMI as measures of risky behaviors (Courtemanche et al. 2017a). Simon, 
Soni and Cawley (2017) found that the Medicaid expansion significantly increased the use of 
some forms of preventative services but did not increase ex ante moral hazard. This study also 
used smoking, heavy drinking, lack of exercise and obesity as proxies for risky behavior. Little 
research has been conducted on the effect of the Medicaid expansion on total opioid use, though 
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a 2018 study found that the Medicaid expansion was not associated with an increase in 
prescription opioids used (Saloner et al. 2018).  
 
Medicaid Expansion and MAT 
 While it probably did not increase the abuse of opioids, the Medicaid expansion increased 
insurance coverage among people receiving treatment for substance abuse. Maclean and Saloner 
(2019) found that expansion led to a 13-percentage point increase (almost double the prior rate) 
in Medicaid paying for service at treatment centers, while state and local governments paid for 
less. The study also found that the annual volume of prescriptions used to treat substance abuse 
that were paid for by Medicaid increased 31% following expansion. 
 This result was in contrast to the first study relating Medicaid expansion to substance 
abuse treatment, which found that use of substance abuse treatment did not change significantly 
as a result of the expansion. However, the use of overall mental health services did increase 2.1 
percentage points. The uninsured rate also dropped 5.1 points among those with substance abuse 
disorders. Payment by Medicaid for substance abuse treatment increased 7.4 percentage points, 
compared to the 13-point increase found by Maclean and Saloner. The study used data from the 
National Survey on Drug Use and Health encompassing 2011 through 2014 but was only 
descriptive in nature (Saloner et al. 2017).  
Research has also established a link between the Medicaid expansion and specific drugs 
used in MAT. State Medicaid expansions have been associated with a 70 percent increase in the 
number of buprenorphine prescriptions paid for my Medicaid in 2014, representing a 50 percent 
increase in buprenorphine spending. Increasing prescribing capacity of physicians was also 
associated with increased buprenorphine utilization, suggesting that decreasing patient costs or 
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increasing supply of MAT increases access to MAT (Wen et al. 2017). Clemans-Cope, Epstein 
and Kenney (2017) similarly found that spending on buprenorphine, naltrexone, and naloxone by 
Medicaid increased 136% from 2011 to 2016, though this study did not isolate the difference 
between expansion and non-expansion states.  
A 2018 quasi-experimental study found that the Medicaid expansion significantly 
increased the number of prescriptions for buprenorphine with naloxone per 100,000 residents in 
expansion counties. The study used longitudinal, patient-level retail pharmacy data covering a 
sample of 11.9 million people who had filled at least two prescriptions for opioids over a five-
year period. Only data from California, Maryland, and Washington (expansion states) and 
Florida and Georgia (not expansion) were used. Using a difference-in-difference regression 
model, the study found that the expansion increased the number of prescriptions for 
buprenorphine with naloxone per 100,000 residents as well as the proportion of the costs paid for 
by Medicaid. There was no effect of the expansion on the number of opioid pain reliever 
prescriptions filled, nor on the number of prescription days of buprenorphine filled (Saloner et al. 
2018).  
 
Methods 
Research Question 
This study seeks to answer whether the increase in MAT prescriptions filled was due to 
existing centers treating more patients, or more centers gaining MAT capacity. On January 1, 
2014, the expanded Medicaid program in 25 states plus DC went into effect. Millions of people 
in these states gained health insurance that they had not previously had. The percent of substance 
abuse treatment centers offering MAT in all states had been rising steadily from 2011 to 2014 
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and continued to do so until 2017. What is not known is whether the expansion of Medicaid 
induced a supply response in states that expanded the program compared to states that did not. 
Did the Medicaid expansion cause substance abuse treatment centers in expansion states to add 
the capacity to treat OUD with MAT?  
 
Hypothesis 
The percent of substance abuse treatment centers offering MAT increased more in 
expansion states than non-expansion states after the Medicaid expansion went into effect.  
 
Data 
 The dataset used for this analysis is the National Survey of Substance Abuse Treatment 
Services (N-SSATS). The survey has been conducted by the Substance Abuse and Mental Health 
Services Administration (SAMHSA) intermittently since the 1970s under different names but 
has been collected every year since 2002 as the N-SSATS. The survey is administered to all 
facilities in the nation that provide substance abuse treatment or detoxification. From 2011 to 
2017, the years used in this study, an average of 92% of facilities responded to the survey with a 
low of 89% in 2017 and a high of 94%. An additional percent of centers is excluded each year if 
they are found to be ineligible after completing the survey, leaving an average of 14,027 centers 
included in the annual dataset (see Appendix A for more information).  
While facilities are given a unique identifier in each year, this identifier changes from 
year to year, so it is impossible to track a specific treatment center across years. However, from 
2011 to 2017 an average of 89% of facilities included in each annual dataset had also responded 
to the prior year’s survey. Most centers that complete the survey do so every year. Of course, 
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notable shifts in treatment center characteristics do occur over time. In 2011, 57% of facilities 
were private and non-profit, while 31% were private for-profit. By 2017, only 53% of private 
facilities were non-profit and 36% were for-profit. A higher percent of for-profit facilities offer 
MAT than non-profits (in 2017, 44% vs. 36%, respectively). The client make-up also changed. 
In 2017, the largest group of patients were in treatment for drug abuse only (244 patients per 
100,000 adults), while in 2011 the largest group of clients were being treated for both alcohol 
and drug abuse. Only 183 patients per 100,000 adults sought treatment for drug abuse alone in 
2011, 25% fewer patients than in 2017. This can largely be attributed to the increased use of 
opioids during this time period. 
 The survey collects data about facility characteristics (ownership, size, organizational 
setting, licensure, fee structure, etc.), services offered (types of care, special client programs, 
conditions treated, etc.), and the number of clients in treatment on March 31st of that year. The 
data is reported at the individual facility level, though responses to many of the survey questions 
are excluded from the dataset each year. Data on the provision of five pharmacotherapies related 
to MAT has been collected and reported every year from 2011 to 2017: oral naltrexone, 
injectable naltrexone, methadone, buprenorphine with naloxone, and buprenorphine without 
naloxone. The 2017 survey also includes buprenorphine sub-dermal implant as an option. The 
survey in 2010 and earlier only included four pharmacotherapies used for MAT, which is why 
2011 is used as the first year in this study.  
 
Methodology 
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The design for this study is a quasi-experimental design using the differences in states’ 
choices to expand Medicaid as a treatment. It uses the following difference-in-difference 
regression to determine whether the percent of centers offering MAT increased more in 
expansion states than in non-expansion states: 
 
𝑦𝑦 =  𝛽𝛽0 + 𝛽𝛽1𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 + 𝛽𝛽2𝑃𝑃𝐺𝐺𝑃𝑃𝑃𝑃𝐺𝐺𝑃𝑃𝑃𝑃 + 𝛽𝛽3𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 ∗ 𝑃𝑃𝐺𝐺𝑃𝑃𝑃𝑃𝐺𝐺𝑃𝑃𝑃𝑃 + 𝜖𝜖 
 
where Group is a binary indicator for whether or not a treatment center was in an expansion state 
or not and PrePost is a binary indicator for whether the observation falls before or after the 
treatment (Medicaid expansion). The reference date of the annual survey is March 31 of that 
year, and data is collected between March and December of that year. Thus, the 2014 survey was 
collected after the expanded coverage went into effect on January 1st. The pre-event period 
includes data from the 2011 to 2013 surveys, while the post-event period covers 2014 to 2017 
(the most recent data available).  
In this difference-in-differences model, the percent of treatment centers offering MAT is 
the outcome variable of interest. These data have been grouped at the group-year level, then 
weighted by the quantity of centers in each observation. 
In order to conduct difference-in-differences analysis, this study first seeks to determine 
the existence of parallel trends in the pre-event period. To do so, a standard regression model 
will be used with dummy variables for each year observed (exclusive of the treatment year): 
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𝑦𝑦 =  𝛽𝛽0 + 𝛽𝛽1𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 + 𝛽𝛽2𝑃𝑃𝐺𝐺𝑃𝑃𝑃𝑃𝐺𝐺𝑃𝑃𝑃𝑃 + 𝛽𝛽3𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 ∗ 𝑦𝑦𝑃𝑃𝑦𝑦𝐺𝐺2011 + 𝛽𝛽4𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 ∗ 𝑦𝑦𝑃𝑃𝑦𝑦𝐺𝐺2012+ 𝛽𝛽5𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 ∗ 𝑦𝑦𝑃𝑃𝑦𝑦𝐺𝐺2014 + 𝛽𝛽6𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 ∗ 𝑦𝑦𝑃𝑃𝑦𝑦𝐺𝐺2015 + 𝛽𝛽7𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 ∗ 𝑦𝑦𝑃𝑃𝑦𝑦𝐺𝐺2016+ 𝛽𝛽8𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 ∗ 𝑦𝑦𝑃𝑃𝑦𝑦𝐺𝐺2017 + 𝜖𝜖 
 
where if the effects of the 2011 and 2012 terms (prior to Medicaid) are insignificant, then the two 
groups followed parallel trends in the pre-event period.  
 
Test Groups 
Expansion states: 
 States that expanded Medicaid on January 1, 2014 form the test group of this study. This 
list includes DC plus the following 25 states: Arkansas, Arizona, California, Colorado, 
Connecticut, Delaware, Hawaii, Iowa, Illinois, Kentucky, Massachusetts, Maryland, Michigan, 
Minnesota, North Dakota, New Jersey, New Mexico, Nevada, New York, Ohio, Oregon, Rhode 
Island, Vermont, Washington, and West Virginia. Some of these states expanded Medicaid early 
under the ACA. Connecticut and DC expanded coverage in 2010, and California, Minnesota, 
New Jersey, and Washington expanded coverage in 2011. However, they all additionally 
increased coverage on the national expansion date of January 1, 2014. Data shows that in most 
early expansion states, the initial early coverage increase was limited compared to the increase 
on the national rollout date (Sommers, Kenney and Epstein 2014). For example, New Jersey 
enrolled four times as many new beneficiaries into Medicaid in 2014 as in 2011. California 
enrolled eight times as many, and Washington state 70 times as many. Minnesota and 
Connecticut were the only states whose early expansions enrolled more people than the 2014 
expansion. However, both states still saw large enrollment gains in 2014. 
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 Massachusetts, New York, Maine and Arizona also conducted significant expansions of 
Medicaid in the early 2000s, unrelated to the ACA, before expanding Medicaid again under the 
ACA. These states are nonetheless included for two main reasons. First, they also saw significant 
coverage gains in 2014. Second, and more importantly, the nature of state-run Medicaid 
programs prior to the ACA inherently means that every state included in analysis will reach 2014 
with different levels of Medicaid coverage. Some states did not cover childless adults while 
others covered adults more generously than the ACA stipulations. The fact that the state made an 
additional expansion of Medicaid coverage is more important than the coverage level before 
expansion.   
Non-expansion states: 
States that did not expand Medicaid or decide to expand Medicaid under the ACA before 
Jan 1, 2018 form the control/comparison group for this study. Because the analysis only covers 
data through 2017, it is safe to include states that made the decision to expand in 2018 or later. 
This group includes the following 18 states: Alabama, Florida, Georgia, Idaho, Kansas, Missouri, 
Mississippi, North Carolina, Nebraska, Oklahoma, South Carolina, South Dakota, Tennessee, 
Texas, Utah, Virginia, Wisconsin, and Wyoming.  
 
Definition of MAT 
 For the purposes of this study, a treatment center is defined as providing MAT if it offers 
any of the six pharmacotherapies used in MAT and covered in the 2011-2017 N-SSATS survey. 
This includes: oral naltrexone, injectable naltrexone, methadone, buprenorphine with naloxone, 
buprenorphine without naloxone, and the buprenorphine sub-dermal implant.  
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Results  
For centers offering at last one form of MAT 
Figure 4 presents a visual representation of the percent of treatment centers offering MAT in 
each group and year.   
Figure 4: 
 
 
Execution of the model for determining parallel trends confirms that the expansion group 
and non-expansion group experienced parallel trends before the event date in 2014, validating 
the use of a difference-in-difference test to determine the effect of the Medicaid expansion. 
Figure 5 shows the estimates for the effects of the pre-event fixed effect year terms to be 
insignificant.  
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Figure 5: 
 
Results of the subsequent difference-in-differences analysis estimate a very slight 
difference in the percent of centers offering MAT before and after the expansion of Medicaid in 
2014, producing a confidence interval of (-4.11%, 4.87%) centered at a mean of 0.38%.  Given 
its sizeable standard error, this estimate is insignificant. Therefore, this analysis concludes that 
the Medicaid expansion had no significant effect on the percent of centers choosing to offer 
MAT. 
Figure 6: 
 
For centers offering buprenorphine with naloxone  
Previous studies estimating the impact of the Medicaid on the availably of MAT have 
focused mainly on buprenorphine with naloxone rather than any MAT drugs. It is therefore 
useful to check the robustness of the previous results using the outcome variable of percent of 
centers offering buprenorphine with naloxone rather than percent of centers offering MAT. The 
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state treatment and control groups remain the same. Figure 7 presents a visualization of the 
percent of substance abuse treatment centers offering buprenorphine with naloxone in each group 
and year. 
Figure 7: 
 
 
Again, the two groups demonstrate parallel trends before 2014. Figure 8 shows the 
estimates for the effects of the pre-event fixed effect year terms to be insignificant. 
Figure 8: 
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Execution of the difference-in-differences analysis again shows a slight difference in the 
percent of centers offering MAT before and after the expansion of Medicaid in 2014, with a 
confidence interval of (-2.14%, 6.18%) centered at a mean of 2.02%. This estimate is also 
insignificant; the Medicaid expansion had no significant effect on the percent of centers choosing 
to offer buprenorphine with naloxone. 
Figure 9: 
 
Discussion  
These results reject the hypothesis that substance abuse treatment centers in expansion 
states added MAT capacity more than in non-expansion states. The Medicaid expansion does not 
appear to have induced a supply response among treatment centers, even though millions of 
people gained the ability to pay for addiction treatment services should they need them. This 
result makes sense in light of the high barriers to gain certification to provide MAT drugs. The 
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OTP certification process, through which a center can prescribe methadone, can take years. It 
can also take time to find a doctor who is licensed to prescribe buprenorphine or to train existing 
doctors. Many substance abuse treatment centers do not have doctors affiliated with them, which 
is required to prescribe buprenorphine or naltrexone. Centers additionally have to be operating at 
or near capacity for it to make financial sense to increase capacity.  
This study has a number of limitations, the most important of which involves the data 
itself. Because the unique identifier for a treatment center is not preserved from year to year in 
the data, it is impossible to track the responses of individual centers across the study period. The 
best that can be done is to use aggregate outcome variables, like percent of centers in a group of 
states offering MAT. The reasonably high annual response rate of 92% (see Appendix A) 
ensures that most eligible centers are included in every year. However, centers do close, open, 
stop offering addiction treatment or begin offering addiction treatment. There are therefore more 
ways than just not responding to the survey that a treatment center can appear or disappear from 
a year’s data. There are also other care settings that can dispense MAT drugs in addition to 
substance abuse treatment centers. Doctors with a license can prescribe buprenorphine and 
naltrexone, whether or not they are associated with a treatment center. However, substance abuse 
treatment centers provide the majority of addiction treatment services in the country. They form 
an integral part of the network of resources for those seeking help with OUD or other addiction.  
This research has important policy implications. MAT has been shown to be more 
effective than other methods of treatment for OUD. Not only does it save lives, but also helps 
those with OUD gain employment, stay in the workforce, and lead normal lives. In 2017, 2.1 
million people suffered from OUD; with extraordinarily low unemployment, the nation benefits 
from helping these people live normal lives. This research shows that if lawmakers want to 
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expand access to MAT, it is not enough to increase the population of people who can pay for the 
therapy. Additional incentives need to be offered to motivate treatment centers to add capacity to 
treat MAT. Another strategy may require lowering the barriers to enter the MAT provision 
market. Lawmakers and medical governing bodies could lower the requirements one needs to 
meet to offer MAT. However, with the high potential for diversion of methadone and 
buprenorphine, this strategy may not make political sense.  
 
 
Conclusion 
 
 Though the ACA Medicaid expansion led to an increase in buprenorphine prescriptions, 
buprenorphine paid for by Medicaid, and number of adults in substance abuse treatment covered 
by Medicaid, it did not cause substance abuse treatment centers to add the ability to provide 
MAT in addition to existing plans. It is heartening that the rate of centers offering MAT 
continues to rise in both expansion and non-expansion states, but policy-makers will have to turn 
to other methods to induce treatment centers to add MAT capacity. While insurance and ability 
to pay are critical factors deciding whether or not an individual seeks treatment, researchers must 
still consider access to treatment. In many states, still fewer than 20% of substance abuse 
treatment centers offer MAT. This means that people suffering from OUD lack access to the 
most effective method of treatment, which prohibits them from reaching their full capacity in life 
and personal relationships. More still needs to be done to ensure that people can take advantage 
of life-changing treatments.   
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Appendix A: 
 
 
 
• Year is the year in which the survey took place 
• Universe includes all substance abuse treatment centers known to SAMHSA 
• Eligible universe includes all centers that are still open and still provide substance abuse 
treatment 
• Response rate denotes the percent of centers in the eligible universe that responded to the 
survey 
• Number responded is the number of centers that responded to the survey in that year 
• Number included is the number of centers that were included in the final dataset 
• % Included in prior year is the number of centers in that year’s dataset that were also 
included in the prior year 
• Client census is the number of clients in treatment on March 31st of that year in all 
treatment centers 
• Clients per 100k adult population is the number of clients in treatment on March 31st, 
divided by the adult population of the country 
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